Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory mCRC completed April 6, 2023
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01; DisTinGuish Trial of DKN-01 + tislelizumab & chemo to continue as a clinical collaboration March 31, 2023
Ph 1b/2 Study initiated to Evaluate Pepinemab + Avelumab in 2L Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients March 31, 2023
QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 March 31, 2023
FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer March 15, 2023
AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate February 28, 2023
Imfinzi plus Imjudo approved in the EU for patients with 1L HCC and mNSCLC based on significant survival benefits in HIMALAYA and POSEIDON Ph 3 trials February 28, 2023
NMPA grants Tislelizumab + chemo approval for 1L use in advanced gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression February 28, 2023
Akamis Bio, Parker Institute for Cancer Immunotherapy and Cancer Research Institute Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer February 22, 2023
Trilaciclib Ph 3 PRESERVE 1 trial in CRC patients to discontinue after absence of efficacy signals in early data February 22, 2023
Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer February 22, 2023
KEYTRUDA + Chemo Significantly Improved OS vs chemo Alone in With HER2-Neg Gastric or GEJ Adenocarcinoma Patients Regardless of PD-L1 Expression February 22, 2023
FDA grants Fast Track designation for KIN-3248 for the treatment of patients with metastatic cholangiocarcinoma February 22, 2023
US FDA Advisory Committee votes in support of trials designed to evaluate Jemperli as a potential treatment for MMR-D/MSI-high locally advanced rectal cancer February 22, 2023
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with Atezolizumab to Treat Gastric Cancer February 8, 2023
First Patient Dosed in VIRAGE, a Ph 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma February 1, 2023
ASCO GI: OS Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory mCRC presented February 1, 2023
Pivotal Data for Futibatinib in Previously Treated Patients With Metastatic Intrahepatic Cholangiocarcinoma published in the NEJM February 1, 2023
ASCO GI: Positive findings in 3L+ metastatic pancreatic cancer patients with doubled OS versus historical OS announced from trial QUILT 88 February 1, 2023
ASCO GI: 84% Overall Survival at 18 Months from Ph 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma announced February 1, 2023
